Walk Test

Boehringer Ingelheim and Eli Lilly and Co. announced negative top-line results for its EMPERIAL-Reduced and EMPERIAL-Preserved trials, nothing that the SGLT2 inhibitor empagliflozin did not meet the primary endpoint of improvements in exercise ability according to the 6-minute walk test from baseline to 12 weeks compared with placebo in patients with chronic HF with reduced and preserved ejection fraction.

Patients with chronic stroke who participated in high-intensity step training had greater improvements in gait symmetry and walking ability compared with those who participated in low-intensity training, according to a study published in Stroke.